Prostate Cancer | Specialty

PROfound Trial With Olaparib Shows Feasibility of Personalizing Care in mCRPC

October 15th 2020

Maha H.A. Hussain, MD, FACP, FASCO, discusses the updated findings from the PROfound trial, its clinical significance in the treatment of patients with mCRPC paradigm, and the promise of precision medicine.

Dr. Shore on the HERO Trial With Relugolix in Advanced Prostate Cancer

October 15th 2020

Neal D. Shore, MD, FACS, discusses the results from the phase 3 HERO trial with relugolix in men with advanced prostate cancer.

Sipuleucel-T Plus Androgen-Receptor Signaling Pathway Inhibitors Boosts OS in Real-World mCRPC Analysis

October 15th 2020

The addition of sipuleucel-T to the androgen-receptor signaling pathway inhibitors abiraterone acetate or enzalutamide reduced the risk of death by 41% and extended median overall survival by 14.5 months in patients with metastatic castration-resistant prostate cancer, irrespective of treatment order.

Dr. Hussain on Rationale to Explore Relationship Between PSA and Outcomes in Nonmetastatic CRPC

October 13th 2020

Maha Hussain, MD, FACP, FASCO, discusses the design of the phase 3 PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer.

Relugolix Continues to Showcase Encouraging Efficacy, Safety in Advanced Prostate Cancer

October 13th 2020

Neal D. Shore, MD, FACS, spotlights relugolix, a novel, gonadotropin-releasing hormone antagonist, that shows great promise in the advanced prostate cancer armamentarium.

Dr. McDermott on the Next Steps of the DASL-HiCAP Trial in High-Risk Prostate Cancer

October 12th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.

Hackensack University Medical Center Urologists Offer Pioneering Clinical Trial to Study Nerve Recovery after Robotic Prostatectomy for Prostate Cancer

October 12th 2020

Department of Urology uses bioregenerative medicine to improve erectile function and continence after robotic radical prostatectomy.

VERU-111 Gains Traction in Overcoming Acquired Resistance in mCRPC

October 9th 2020

Philip W. Kantoff, MD, discusses the evolving treatment landscape of mCRPC, the early efficacy data demonstrated with VERU-111, and other emerging areas of research that are poised to impact the prostate cancer paradigm.

Dr. Kantoff on the Need to Develop New Therapies in mCRPC

October 8th 2020

Philip W. Kantoff, MD, discusses the need to develop new therapies in metastatic castration-resistant prostate cancer.

Rapid Readouts: Phase 3 HERO Trial

October 8th 2020

Dr. Petrylak on the Utility of Tissue Versus Liquid Biopsy in Prostate Cancer

October 7th 2020

Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.

New Framework for Genetic Testing in Prostate Cancer Takes Shape

October 7th 2020

In recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.

Dr. Hussain on the Need for Collaboration to Cure Prostate Cancer

October 6th 2020

Maha Hussain, MD, FACP, FASCO, discusses the need for collaboration to cure patients with prostate cancer.

Dr. Azad on the Benefit of Adding Enzalutamide to ADT in mHSPC

October 5th 2020

Arun Azad, PhD, discusses the utility of adding enzalutamide to androgen deprivation therapy in subgroups of men with metastatic hormone-sensitive prostate cancer.

Dr. Kantoff on Approaches for Progressive Prostate Cancer Following Androgen Blockade

October 1st 2020

Philip W. Kantoff, MD, discusses current approaches for patients with metastatic hormone-sensitive prostate cancer, and nonmetastatic/metastatic castration-resistant prostate cancer who progress on androgen blocking agents.

PSA Responses to Enzalutamide Significantly Associated With Longer MFS in nmCRPC

October 1st 2020

Maha H.A. Hussain, MD, FACP, FASCO, discusses the prognostic associations of depth of PSA responses with MFS in patients with nmCRPC and a rapidly rising PSA who have been treated with enzalutamide and other efforts being made in this disease.

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer

September 30th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.

Dr. Nguyen on Treatment Considerations in High-Risk Prostate Cancer

September 29th 2020

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

Dr. Choudhury on the Designs of Key Trials in Nonmetastatic CRPC

September 29th 2020

Atish D. Choudhury, MD, PhD, discusses the design of key clinical trials in nonmetastatic castration-resistant prostate cancer.

Dr. Hussain on the Rationale to Target the DNA Repair Pathway in mCRPC

September 29th 2020

Maha Hussain, MD, FACP, FASCO, discusses the rationale for targeting the DNA repair pathway in metastatic castration-resistant prostate cancer.